Aspirin is one of the most promising chemo preventive agents for CRC, and it has been shown that aspirin inhibits inflammation-induced colorectal carcinogenesis by reducing COX2 and ROS levels, thereby reducing DNA damage and oncogenic YAP1 (33). This evidence concerns the gene YAP1 and colorectal carcinoma.